Therefore, a variety of potential biomarkers are now being assessed to predict immunotherapeutic efficacy in breast cancer beyond PD-L1 expression, including gene signatures, TILs, tumor mutational burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) deficiency. This evidence concerns the gene CD274 and breast carcinoma.